Colgate-Palmolive (CL) Draws Q2 Attention, Is The Valuation Already Priced In?
Q2 Earnings Anticipation and Dividend Move Put Colgate-Palmolive in Focus
Colgate-Palmolive (CL) is in the spotlight as investors look ahead to Q2 results, with attention on international performance, organic sales trends, and a higher quarterly dividend of US$0.53 per share.
See our latest analysis for Colgate-Palmolive.
At a share price of US$90.75, Colgate-Palmolive has had a mixed near term patch, with the share price return declining 2.4% over the past week but rising 7.8% over 90 days and supported by a 16.8% year to date share price return and 5.8% one year total shareholder return, which together suggest momentum has been building rather than fading.
If this earnings driven move has you thinking about what else might be setting up for a similar shift, it could be worth scanning 18 top founder-led companies
Colgate-Palmolive looks like a solid global franchise with long established brands and a fresh dividend lift. After the recent share price run, is the stock still offering value, or has the quality already been fully priced in?
Most Popular Narrative: 6.1% Undervalued
Colgate-Palmolive's most followed narrative points to a fair value of $96.68 per share versus the last close at $90.75, putting the focus firmly on what is driving that gap.
Expansion and premiumization of core oral care lines like Colgate Total, coupled with the roll-out of complementary products across 75 markets, are set to capture increased value from emerging middle-class consumers and rising health/hygiene awareness globally, which is expected to support top-line organic sales acceleration and improved pricing power.
Want to see what sits behind that growth story for Colgate-Palmolive? The narrative leans on steady revenue gains, wider margins, and a future earnings profile that assumes a higher than average earnings multiple. Curious which assumptions really carry the $96.68 fair value and how sensitive that is to growth slowing or margins stalling?
Result: Fair Value of $96.68 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Colgate-Palmolive's story can quickly look different if raw material and packaging costs remain elevated or if weaker demand in markets like China and India persists.
Find out about the key risks to this Colgate-Palmolive narrative.
Another View on Colgate-Palmolive’s Valuation
The first narrative leans on discounted future earnings to argue Colgate-Palmolive looks 6.1% undervalued, yet the simple earnings multiple tells a different story. At a P/E of 34.8x versus a fair ratio of 23.9x and a Global Household Products average of 16.5x, the stock looks richly priced relative to both its own fair ratio and peers. That gap raises a practical question for investors: is the current price already baking in much of the optimism?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Uncertain whether the overall tone on Colgate-Palmolive should leave you cautious or confident? Act quickly, review the full picture, and weigh the 3 key rewards and 3 important warning signs.
Looking For More Investment Ideas Beyond Colgate-Palmolive?
If the Colgate-Palmolive story has you thinking more broadly about your portfolio, do not stop here. Stronger ideas often appear when you compare several high quality stocks side by side.
- Target resilient growth potential by scanning screener containing 19 high quality undiscovered gems that combine solid fundamentals with limited market attention.
- Strengthen your income stream and review 9 dividend fortresses that focus on higher yielding stocks with a focus on durability.
- Dial back risk while staying invested by using 79 resilient stocks with low risk scores designed to highlight companies with more resilient profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com